查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1611236

代謝紊亂治療的市場規模、佔有率和趨勢分析報告：按疾病、治療方法、給藥途徑、分銷管道、地區和細分市場進行預測，2025-2030年

Metabolic Disorder Therapeutics Market Size, Share & Trends Analysis Report By Disease, By Therapy, By Route Of Administration (Oral, Parenteral), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

代謝紊亂治療市場的成長與趨勢

Grand View Research, Inc.最新報告顯示，預計到2030年，全球代謝疾病治療市場規模將達到1,207.1億美元，2025年至2030年複合年成長率為7.8%。糖尿病、肥胖症和高膽固醇症的增加預計將推動市場成長。據估計，到 2040 年，全球大約每 11 人中就有 1 人將受到上述疾病之一的影響。

負責人預測，未來20年，肥胖和糖尿病等代謝性疾病的盛行率將翻倍，尤其是在美國以及亞洲和拉丁美洲國家。預計這將支持整個市場的未來成長。此外，隨著新興國家經濟的穩定，對一次性治療的新療法的需求正在增加。因此，全球市場的領先公司正在大力投資研發，以開發創新治療方法。所有這些因素都可能有助於市場發展。

代謝紊亂治療市場報告亮點

  • 糖尿病在市場上佔據主導地位，到 2024 年將佔 29.8% 的佔有率。這是由於糖尿病，特別是第 2 型糖尿病的盛行率不斷上升，影響了全球 5% 以上的人口。
  • 溶小體貯積症 (LSD) 預計在預測期內將以 9.3% 的最快複合年成長率成長。 LSD 是一種由酵素缺乏引起的進行性神經系統疾病，會導致嚴重症狀和過早死亡。
  • 酵素替代療法（ERT）在 2024 年以 30.6% 的銷售佔有率引領市場。 ERT 針對與溶小體貯積症相關的基本酵素缺乏症，並顯著改善患者的健康和生活品質。
  • 基因治療預計在預測期內成長最快，達到 9.7%。基因療法具有巨大的潛力，可以為治療選擇有限的遺傳性代謝疾病提供治療解決方案。
  • 由於起效快和生物利用度高，腸外治療在 2024 年佔據了最大的市場佔有率，達到 50.0%。腸胃外給藥可有效繞過胃腸道，以避免首過代謝並提供即時的治療效果。
  • 預計口服治療在預測期內的複合年成長率將達到 8.2%。口服給藥是非侵入性的，更容易讓患者自行給藥，通常優於注射，可提高治療順從性
  • 醫院藥局佔據市場主導地位，2024 年銷售佔有率為 44.6%。醫院藥局在配發複雜藥物方面發揮重要作用，尤其是那些需要專門處理的代謝性疾病藥物。
  • 北美代謝紊亂治療市場在2024年以39.9%的銷售佔有率主導全球市場。北美擁有強大的醫療基礎設施、大量的研發投資以及糖尿病和肥胖等代謝疾病的高發生率。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章代謝性疾病治療市場變數、趨勢與範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 營商環境分析
    • 產業分析-波特五力分析
    • PESTLE分析

第4章代謝紊亂治療市場：疾病業務分析

  • 2024年及2030年疾病市場佔有率
  • 疾病細分儀表板
  • 2018-2030 年按疾病分類的市場規模、預測與趨勢分析
  • 溶小體貯積症
  • 糖尿病
  • 肥胖
  • 遺傳性代謝疾病
  • 高膽固醇症
  • 其他代謝性疾病

第5章代謝紊亂治療市場：治療方法業務分析

  • 2024 年和 2030 年治療方法市場佔有率
  • 治療方法細分儀表板
  • 2018-2030 年市場規模及預測與趨勢分析（按治療方法）
  • 酵素替代療法
  • 細胞移植
  • 基於小分子的治療方法
  • 基材減少療法
  • 基因治療
  • 藥物治療

第6章代謝性疾病治療市場：給藥途徑業務分析

  • 2024 年及 2030 年給藥途徑市場佔有率
  • 細分儀表板
  • 2018-2030 年按管理方式分類的市場規模、預測與趨勢分析
  • 口服
  • 胃腸外的
  • 其他

第7章代謝性疾病治療市場：通路業務分析

  • 2024 年及 2030 年分銷通路市場佔有率
  • 分銷通路細分儀表板
  • 2018-2030 年按分銷管道分類的市場規模、預測與趨勢分析
  • 醫院藥房
  • 零售藥房
  • 網路藥房

第8章代謝紊亂治療市場：按疾病、治療方法、給藥途徑和分銷管道分類的地區估計和趨勢分析

  • 2024 年及 2030 年按地區分類的市場佔有率分析
  • 區域市場儀表板
  • 2018-2030年市場規模、預測趨勢分析
  • 北美洲
    • 按國家/地區分類，2018-2030
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 按國家/地區分類，2018-2030
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 丹麥
    • 瑞典
  • 亞太地區
    • 按國家/地區分類，2018-2030
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 按國家/地區分類，2018-2030
    • 巴西
    • 阿根廷
  • 中東/非洲
    • 按國家/地區分類，2018-2030
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第9章 競爭格局

  • 參與者概覽
  • 公司市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介/上市公司
    • Novo Nordisk A/S
    • Eli Lilly and Company
    • Takeda Pharmaceutical Company Limited
    • Sanofi
    • Merck KGaA
    • AstraZeneca
    • AbbVie Inc.
    • Johnson & Johnson Innovative Medicine
    • Amgen Inc.
    • Biocon
    • BioMarin
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb Company
    • Cipla Inc.
Product Code: GVR-3-68038-011-8

Metabolic Disorder Therapeutics Market Growth & Trends:

The global metabolic disorder therapeutics market size is expected to reach USD 120.71 billion by 2030, registering a CAGR of 7.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. Rising incidences of diabetes, obesity, and hypercholesterolemia are expected to drive the market growth. It is estimated that by 2040, about 1 person in 11 people worldwide is likely to suffer from one of the aforementioned diseases.

Researchers estimate that the prevalence of metabolic diseases like obesity and diabetes is expected to double in the coming 2 decades, mainly in U.S. and Asian and Latin American countries. This, in turn, will help boost the overall market growth in the year to come. Furthermore, with better economic stability in developing countries, demand for novel therapeutics for one-time treatment has increased. This has made major companies in the global market to invest heavily in R&D to develop innovative therapy options. All these factors will contribute to the development of the market.

Metabolic Disorder Therapeutics Market Report Highlights:

  • Diabetes dominated the market and accounted for a share of 29.8% in 2024, driven by the increasing prevalence of diabetes, particularly type 2 diabetes, affecting more than 5% of the global population.
  • Lysosomal storage diseases (LSDs) are expected to grow at the fastest CAGR of 9.3% over the forecast period. LSDs are progressive neurological conditions resulting from enzyme deficiencies, causing severe symptoms and early mortality.
  • Enzyme replacement therapy (ERT) led the market with a revenue share of 30.6% in 2024. ERT targets the fundamental enzyme deficiencies associated with lysosomal storage disorders, significantly improving patient health and quality of life.
  • Gene therapy is anticipated to witness the fastest rate of 9.7% over the forecast period. Gene therapy holds significant potential to offer curative solutions for inherited metabolic diseases with limited treatment options.
  • Parenteral therapeutics held the largest market share of 50.0% in 2024, aided by rapid onset of action and high bioavailability. Parenteral administration effectively bypasses the gastrointestinal tract, avoiding first-pass metabolism, crucial for immediate therapeutic effects.
  • Oral therapeutics are expected to register the fastest CAGR of 8.2% over the forecast period. Oral administration is non-invasive, easy for patients to self-administer, and typically preferred over injections, resulting in higher treatment adherence.
  • Hospital pharmacies dominated the market with a revenue share of 44.6% in 2024. Hospital pharmacies play a vital role in dispensing complex medications, particularly for metabolic disorders that necessitate specialized handling.
  • North America metabolic disorder therapeutics market dominated the global market with a revenue share of 39.9% in 2024. North America boasts a strong healthcare infrastructure, substantial investments in research and development, and a notable prevalence of metabolic disorders such as diabetes and obesity.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Disease
    • 1.2.2. Therapy
    • 1.2.3. Route of Administration
    • 1.2.4. Distribution Channel
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Metabolic Disorder Therapeutics Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Metabolic Disorder Therapeutics Market: Disease Business Analysis

  • 4.1. Disease Market Share, 2024 & 2030
  • 4.2. Disease Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Disease, 2018 to 2030 (USD Million)
  • 4.4. Lysosomal Storage Diseases
    • 4.4.1. Lysosomal Storage Diseases Market, 2018 - 2030 (USD Million)
  • 4.5. Diabetes
    • 4.5.1. Diabetes Market, 2018 - 2030 (USD Million)
  • 4.6. Obesity
    • 4.6.1. Obesity Market, 2018 - 2030 (USD Million)
  • 4.7. Inherited Metabolic Disorders
    • 4.7.1. Inherited Metabolic Disorders Market, 2018 - 2030 (USD Million)
  • 4.8. Hypercholesterolemia
    • 4.8.1. Hypercholesterolemia Market, 2018 - 2030 (USD Million)
  • 4.9. Other Metabolic Diseases
    • 4.9.1. Other Metabolic Diseases Market, 2018 - 2030 (USD Million)

Chapter 5. Metabolic Disorder Therapeutics Market: Therapy Business Analysis

  • 5.1. Therapy Market Share, 2024 & 2030
  • 5.2. Therapy Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Therapy, 2018 to 2030 (USD Million)
  • 5.4. Enzyme Replacement Therapy
    • 5.4.1. Enzyme Replacement Therapy Market, 2018 - 2030 (USD Million)
  • 5.5. Cellular Transplantation
    • 5.5.1. Cellular Transplantation Market, 2018 - 2030 (USD Million)
  • 5.6. Small Molecule Based Therapy
    • 5.6.1. Small Molecule Based Therapy Market, 2018 - 2030 (USD Million)
  • 5.7. Substrate Reduction Therapy
    • 5.7.1. Substrate Reduction Therapy Market, 2018 - 2030 (USD Million)
  • 5.8. Gene Therapy
    • 5.8.1. Gene Therapy Market, 2018 - 2030 (USD Million)
  • 5.9. Drug Therapy
    • 5.9.1. Drug Therapy Market, 2018 - 2030 (USD Million)

Chapter 6. Metabolic Disorder Therapeutics Market: Route of Administration Business Analysis

  • 6.1. Route of Administration Market Share, 2024 & 2030
  • 6.2. Route of Administration Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2018 to 2030 (USD Million)
  • 6.4. Oral
    • 6.4.1. Oral Market, 2018 - 2030 (USD Million)
  • 6.5. Parenteral
    • 6.5.1. Parenteral Market, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Metabolic Disorder Therapeutics Market: Distribution Channel Business Analysis

  • 7.1. Distribution Channel Market Share, 2024 & 2030
  • 7.2. Distribution Channel Segment Dashboard
  • 7.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
  • 7.4. Hospital Pharmacies
    • 7.4.1. Hospital Pharmacies Market, 2018 - 2030 (USD Million)
  • 7.5. Retail Pharmacies
    • 7.5.1. Retail Pharmacies Market, 2018 - 2030 (USD Million)
  • 7.6. Online Pharmacies
    • 7.6.1. Online Pharmacies Market, 2018 - 2030 (USD Million)

Chapter 8. Metabolic Disorder Therapeutics Market: Regional Estimates & Trend Analysis by Disease, Therapy, Route of Administration, and Distribution Channel

  • 8.1. Regional Market Share Analysis, 2024 & 2030
  • 8.2. Regional Market Dashboard
  • 8.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 8.4. North America
    • 8.4.1. North America Metabolic Disorder Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.4.2. U.S.
      • 8.4.2.1. Key Country Dynamics
      • 8.4.2.2. Regulatory Framework
      • 8.4.2.3. Competitive Insights
      • 8.4.2.4. U.S. Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.3. Canada
      • 8.4.3.1. Key Country Dynamics
      • 8.4.3.2. Regulatory Framework
      • 8.4.3.3. Competitive Insights
      • 8.4.3.4. Canada Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.4.4. Mexico
      • 8.4.4.1. Key Country Dynamics
      • 8.4.4.2. Regulatory Framework
      • 8.4.4.3. Competitive Insights
      • 8.4.4.4. Mexico Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.5. Europe
    • 8.5.1. Europe Metabolic Disorder Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.5.2. UK
      • 8.5.2.1. Key Country Dynamics
      • 8.5.2.2. Regulatory Framework
      • 8.5.2.3. Competitive Insights
      • 8.5.2.4. UK Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.3. Germany
      • 8.5.3.1. Key Country Dynamics
      • 8.5.3.2. Regulatory Framework
      • 8.5.3.3. Competitive Insights
      • 8.5.3.4. Germany Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.4. France
      • 8.5.4.1. Key Country Dynamics
      • 8.5.4.2. Regulatory Framework
      • 8.5.4.3. Competitive Insights
      • 8.5.4.4. France Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.5. Italy
      • 8.5.5.1. Key Country Dynamics
      • 8.5.5.2. Regulatory Framework
      • 8.5.5.3. Competitive Insights
      • 8.5.5.4. Italy Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.6. Spain
      • 8.5.6.1. Key Country Dynamics
      • 8.5.6.2. Regulatory Framework
      • 8.5.6.3. Competitive Insights
      • 8.5.6.4. Spain Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.7. Norway
      • 8.5.7.1. Key Country Dynamics
      • 8.5.7.2. Regulatory Framework
      • 8.5.7.3. Competitive Insights
      • 8.5.7.4. Norway Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.8. Denmark
      • 8.5.8.1. Key Country Dynamics
      • 8.5.8.2. Regulatory Framework
      • 8.5.8.3. Competitive Insights
      • 8.5.8.4. Denmark Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.5.9. Sweden
      • 8.5.9.1. Key Country Dynamics
      • 8.5.9.2. Regulatory Framework
      • 8.5.9.3. Competitive Insights
      • 8.5.9.4. Sweden Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.6. Asia Pacific
    • 8.6.1. Asia Pacific Metabolic Disorder Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.6.2. Japan
      • 8.6.2.1. Key Country Dynamics
      • 8.6.2.2. Regulatory Framework
      • 8.6.2.3. Competitive Insights
      • 8.6.2.4. Japan Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.3. China
      • 8.6.3.1. Key Country Dynamics
      • 8.6.3.2. Regulatory Framework
      • 8.6.3.3. Competitive Insights
      • 8.6.3.4. China Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.4. India
      • 8.6.4.1. Key Country Dynamics
      • 8.6.4.2. Regulatory Framework
      • 8.6.4.3. Competitive Insights
      • 8.6.4.4. India Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.5. South Korea
      • 8.6.5.1. Key Country Dynamics
      • 8.6.5.2. Regulatory Framework
      • 8.6.5.3. Competitive Insights
      • 8.6.5.4. South Korea Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.6. Australia
      • 8.6.6.1. Key Country Dynamics
      • 8.6.6.2. Regulatory Framework
      • 8.6.6.3. Competitive Insights
      • 8.6.6.4. Australia Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.6.7. Thailand
      • 8.6.7.1. Key Country Dynamics
      • 8.6.7.2. Regulatory Framework
      • 8.6.7.3. Competitive Insights
      • 8.6.7.4. Thailand Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.7. Latin America
    • 8.7.1. Latin America Metabolic Disorder Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.7.2. Brazil
      • 8.7.2.1. Key Country Dynamics
      • 8.7.2.2. Regulatory Framework
      • 8.7.2.3. Competitive Insights
      • 8.7.2.4. Brazil Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.7.3. Argentina
      • 8.7.3.1. Key Country Dynamics
      • 8.7.3.2. Regulatory Framework
      • 8.7.3.3. Competitive Insights
      • 8.7.3.4. Argentina Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
  • 8.8. MEA
    • 8.8.1. MEA Metabolic Disorder Therapeutics Market Estimates And Forecasts, By Country, 2018 - 2030 (USD Million)
    • 8.8.2. South Africa
      • 8.8.2.1. Key Country Dynamics
      • 8.8.2.2. Regulatory Framework
      • 8.8.2.3. Competitive Insights
      • 8.8.2.4. South Africa Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.8.3. Saudi Arabia
      • 8.8.3.1. Key Country Dynamics
      • 8.8.3.2. Regulatory Framework
      • 8.8.3.3. Competitive Insights
      • 8.8.3.4. Saudi Arabia Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.8.4. UAE
      • 8.8.4.1. Key Country Dynamics
      • 8.8.4.2. Regulatory Framework
      • 8.8.4.3. Competitive Insights
      • 8.8.4.4. UAE Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 8.8.5. Kuwait
      • 8.8.5.1. Key Country Dynamics
      • 8.8.5.2. Regulatory Framework
      • 8.8.5.3. Competitive Insights
      • 8.8.5.4. Kuwait Metabolic Disorder Therapeutics Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

  • 9.1. Participant Overview
  • 9.2. Company Market Position Analysis
  • 9.3. Company Categorization
  • 9.4. Strategy Mapping
  • 9.5. Company Profiles/Listing
    • 9.5.1. Novo Nordisk A/S
      • 9.5.1.1. Overview
      • 9.5.1.2. Financial Performance
      • 9.5.1.3. Product Benchmarking
      • 9.5.1.4. Strategic Initiatives
    • 9.5.2. Eli Lilly and Company
      • 9.5.2.1. Overview
      • 9.5.2.2. Financial Performance
      • 9.5.2.3. Product Benchmarking
      • 9.5.2.4. Strategic Initiatives
    • 9.5.3. Takeda Pharmaceutical Company Limited
      • 9.5.3.1. Overview
      • 9.5.3.2. Financial Performance
      • 9.5.3.3. Product Benchmarking
      • 9.5.3.4. Strategic Initiatives
    • 9.5.4. Sanofi
      • 9.5.4.1. Overview
      • 9.5.4.2. Financial Performance
      • 9.5.4.3. Product Benchmarking
      • 9.5.4.4. Strategic Initiatives
    • 9.5.5. Merck KGaA
      • 9.5.5.1. Overview
      • 9.5.5.2. Financial Performance
      • 9.5.5.3. Product Benchmarking
      • 9.5.5.4. Strategic Initiatives
    • 9.5.6. AstraZeneca
      • 9.5.6.1. Overview
      • 9.5.6.2. Financial Performance
      • 9.5.6.3. Product Benchmarking
      • 9.5.6.4. Strategic Initiatives
    • 9.5.7. AbbVie Inc.
      • 9.5.7.1. Overview
      • 9.5.7.2. Financial Performance
      • 9.5.7.3. Product Benchmarking
      • 9.5.7.4. Strategic Initiatives
    • 9.5.8. Johnson & Johnson Innovative Medicine
      • 9.5.8.1. Overview
      • 9.5.8.2. Financial Performance
      • 9.5.8.3. Product Benchmarking
      • 9.5.8.4. Strategic Initiatives
    • 9.5.9. Amgen Inc.
      • 9.5.9.1. Overview
      • 9.5.9.2. Financial Performance
      • 9.5.9.3. Product Benchmarking
      • 9.5.9.4. Strategic Initiatives
    • 9.5.10. Biocon
      • 9.5.10.1. Overview
      • 9.5.10.2. Financial Performance
      • 9.5.10.3. Product Benchmarking
      • 9.5.10.4. Strategic Initiatives
    • 9.5.11. BioMarin
      • 9.5.11.1. Overview
      • 9.5.11.2. Financial Performance
      • 9.5.11.3. Product Benchmarking
      • 9.5.11.4. Strategic Initiatives
    • 9.5.12. Boehringer Ingelheim International GmbH
      • 9.5.12.1. Overview
      • 9.5.12.2. Financial Performance
      • 9.5.12.3. Product Benchmarking
      • 9.5.12.4. Strategic Initiatives
    • 9.5.13. Bristol-Myers Squibb Company
      • 9.5.13.1. Overview
      • 9.5.13.2. Financial Performance
      • 9.5.13.3. Product Benchmarking
      • 9.5.13.4. Strategic Initiatives
    • 9.5.14. Cipla Inc.
      • 9.5.14.1. Overview
      • 9.5.14.2. Financial Performance
      • 9.5.14.3. Product Benchmarking
      • 9.5.14.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global metabolic disorder therapeutics market, by region, 2018 - 2030 (USD Million)
  • Table 4. Global metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 5. Global metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 6. Global metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 7. Global metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 8. North America metabolic disorder therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 9. North America metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 10. North America metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 11. North America metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 12. North America metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 13. U.S. metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 14. U.S. metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 15. U.S. metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 16. U.S. metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 17. Canada metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 18. Canada metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 19. Canada metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 20. Canada metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 21. Mexico metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 22. Mexico metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 23. Mexico metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 24. Mexico metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 25. Europe metabolic disorder therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 26. Europe metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 27. Europe metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 28. Europe metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 29. Europe metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 30. UK metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 31. UK metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 32. UK metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 33. UK metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 34. Germany metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 35. Germany metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 36. Germany metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 37. Germany metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 38. France metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 39. France metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 40. France metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 41. France metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 42. Italy metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 43. Italy metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 44. Italy metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 45. Italy metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 46. Spain metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 47. Spain metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 48. Spain metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 49. Spain metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 50. Denmark metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 51. Denmark metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 52. Denmark metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 53. Denmark metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 54. Sweden metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 55. Sweden metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 56. Sweden metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 57. Sweden metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 58. Norway metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 59. Norway metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 60. Norway metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 61. Norway metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 62. Asia Pacific metabolic disorder therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 63. Asia Pacific metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 64. Asia Pacific metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 65. Asia Pacific metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 66. Asia Pacific metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 67. China metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 68. China metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 69. China metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 70. China metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 71. Japan metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 72. Japan metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 73. Japan metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 74. Japan metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 75. India metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 76. India metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 77. India metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 78. India metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 79. Australia metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 80. Australia metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 81. Australia metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 82. Australia metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 83. South Korea metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 84. South Korea metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 85. South Korea metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 86. South Korea metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 87. Thailand metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 88. Thailand metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 89. Thailand metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 90. Thailand metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 91. Latin America metabolic disorder therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 92. Latin America metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 93. Latin America metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 94. Latin America metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 95. Latin America metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 96. Brazil metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 97. Brazil metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 98. Brazil metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 99. Brazil metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 100. Argentina metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 101. Argentina metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 102. Argentina metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 103. Argentina metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 104. Middle East & Africa Metabolic disorder therapeutics market, by country, 2018 - 2030 (USD Million)
  • Table 105. Middle East & Africa metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 106. Middle East & Africa metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 107. Middle East & Africa metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 108. Middle East & Africa metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 109. South Africa metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 110. South Africa metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 111. South Africa metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 112. South Africa metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 113. Saudi Arabia metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 114. Saudi Arabia metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 115. Saudi Arabia metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 116. Saudi Arabia metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 117. UAE metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 118. UAE metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 119. UAE metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 120. UAE metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 121. Kuwait metabolic disorder therapeutics market, by disease, 2018 - 2030 (USD Million)
  • Table 122. Kuwait metabolic disorder therapeutics market, by therapy, 2018 - 2030 (USD Million)
  • Table 123. Kuwait metabolic disorder therapeutics market, by route of administration, 2018 - 2030 (USD Million)
  • Table 124. Kuwait metabolic disorder therapeutics market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Metabolic disorder therapeutics market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Disease and therapy outlook (USD Million)
  • Fig. 10 Route of administration and distribution channel outlook (USD Million)
  • Fig. 11 Competitive landscape
  • Fig. 12 Metabolic disorder therapeutics market dynamics
  • Fig. 13 Metabolic disorder therapeutics market: Porter's five forces analysis
  • Fig. 14 Metabolic disorder therapeutics market: PESTLE analysis
  • Fig. 15 Metabolic disorder therapeutics market: Disease segment dashboard
  • Fig. 16 Metabolic disorder therapeutics market: Disease market share analysis, 2024 & 2030
  • Fig. 17 Lysosomal storage diseases market, 2018 - 2030 (USD Million)
  • Fig. 18 Diabetes market, 2018 - 2030 (USD Million)
  • Fig. 19 Obesity market, 2018 - 2030 (USD Million)
  • Fig. 20 Inherited metabolic disorders market, 2018 - 2030 (USD Million)
  • Fig. 21 Hypercholesterolemia market, 2018 - 2030 (USD Million)
  • Fig. 22 Other metabolic diseases market, 2018 - 2030 (USD Million)
  • Fig. 23 Metabolic disorder therapeutics market: Therapy segment dashboard
  • Fig. 24 Metabolic disorder therapeutics market: Therapy market share analysis, 2024 & 2030
  • Fig. 25 Enzyme replacement therapy market, 2018 - 2030 (USD Million)
  • Fig. 26 Cellular transplantation market, 2018 - 2030 (USD Million)
  • Fig. 27 Small molecule based therapy market, 2018 - 2030 (USD Million)
  • Fig. 28 Substrate reduction therapy market, 2018 - 2030 (USD Million)
  • Fig. 29 Gene therapy market, 2018 - 2030 (USD Million)
  • Fig. 30 Drug therapy market, 2018 - 2030 (USD Million)
  • Fig. 31 Metabolic disorder therapeutics market: Route of administration segment dashboard
  • Fig. 32 Metabolic disorder therapeutics market: Route of administration market share analysis, 2024 & 2030
  • Fig. 33 Oral market, 2018 - 2030 (USD Million)
  • Fig. 34 Parenteral market, 2018 - 2030 (USD Million)
  • Fig. 35 Others market, 2018 - 2030 (USD Million)
  • Fig. 36 Metabolic disorder therapeutics market: Distribution channel segment dashboard
  • Fig. 37 Metabolic disorder therapeutics market: Distribution channel market share analysis, 2024 & 2030
  • Fig. 38 Hospital pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 39 Retail pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 40 Online pharmacies market, 2018 - 2030 (USD Million)
  • Fig. 41 Metabolic disorder therapeutics market revenue, by region
  • Fig. 42 Regional marketplace: Key takeaways
  • Fig. 43 Regional marketplace: Key takeaways
  • Fig. 44 North America metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 45 U.S. country dynamics
  • Fig. 46 U.S. metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 47 Canada country dynamics
  • Fig. 48 Canada metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 49 Mexico country dynamics
  • Fig. 50 Mexico metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 51 Europe metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 52 UK country dynamics
  • Fig. 53 UK metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 54 Germany country dynamics
  • Fig. 55 Germany metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 56 France country dynamics
  • Fig. 57 France metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 58 Italy country dynamics
  • Fig. 59 Italy metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 60 Spain country dynamics
  • Fig. 61 Spain metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 62 Norway country dynamics
  • Fig. 63 Norway metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 64 Sweden country dynamics
  • Fig. 65 Sweden metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 66 Denmark country dynamics
  • Fig. 67 Denmark metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 68 Asia Pacific metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 69 Japan country dynamics
  • Fig. 70 Japan metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 71 China country dynamics
  • Fig. 72 China metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 73 India country dynamics
  • Fig. 74 India metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 75 Australia country dynamics
  • Fig. 76 Australia metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 77 South Korea country dynamics
  • Fig. 78 South Korea metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 79 Thailand country dynamics
  • Fig. 80 Thailand metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 81 Latin America metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 82 Brazil country dynamics
  • Fig. 83 Brazil metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 84 Argentina country dynamics
  • Fig. 85 Argentina metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 86 MEA metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 87 South Africa country dynamics
  • Fig. 88 South Africa metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 89 Saudi Arabia country dynamics
  • Fig. 90 Saudi Arabia metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 91 UAE country dynamics
  • Fig. 92 UAE metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 93 Kuwait country dynamics
  • Fig. 94 Kuwait metabolic disorder therapeutics market, 2018 - 2030 (USD Million)
  • Fig. 95 Company categorization
  • Fig. 96 Company market position analysis
  • Fig. 97 Strategic framework